Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
2022studies shown
Showing 1,201-1,225 of 2,022
CompletedNCT04414930

Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia

This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
University of California, San Diego
Condition
Schizophrenia
CompletedNCT02627716

Joint Crisis Plan Effectiveness in Preventing Relapses in Schizophrenia and Schizoaffective Disorder

This study exists to compare options and see whether questionnaires and follow-up reports offers something meaningfully different. Researchers are trying to understand whether questionnaires and follow-up reports can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
France
Sponsor
University Hospital, Lille
Condition
Schizophrenia
CompletedNCT05664594

State Representation in Early Psychosis - Project 4

This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 15 Years to 45 Years
Countries
United States
Sponsor
University of Minnesota
Condition
Schizophrenia
CompletedNCT04846881

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

This study exists to learn from real-world information that can show how the medication Iclepertin fits into care. Researchers are trying to understand whether the medication Iclepertin can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Argentina, Brazil, Chile, Croatia, France, Hungary, Japan, Malaysia, Netherlands, Poland, Romania, Serbia, Singapore, Slovakia, South Korea, Spain, Ukraine, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT05741528

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT05628103

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand whether a medication treatment can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT01964404

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

This study exists to see whether smoking support or smoking-related treatment is workable and worth testing more broadly. Researchers are trying to understand whether smoking support or smoking-related treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Dartmouth-Hitchcock Medical Center
Condition
Schizophrenia
WithdrawnNCT05939765

Pharmacologic Treatment in Legal Offenders With Schizophrenia, a Prospective Observational Mirror Image Study.

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Switzerland
Sponsor
Psychiatric University Hospital, Zurich
Condition
Schizophrenia
CompletedNCT07268430

Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia

This study exists to better understand the safety of the medication Long-Acting and how manageable it feels in practice. Researchers are trying to understand how people respond to the medication Long-Acting in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
China
Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Condition
Schizophrenia
CompletedNCT05480046

Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse

This study exists to understand whether the medication Risperidone is both safe enough and useful enough to take further. Researchers are trying to understand whether the medication Risperidone can better prevent setbacks and support longer-term stability.

SchizophreniaOtherOver 18 Years
Countries
Germany, Italy, Portugal, Spain, United Kingdom
Sponsor
Rovi Pharmaceuticals Laboratories
Condition
Schizophrenia
CompletedNCT06136390

OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia

This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 75 Years
Countries
Germany
Sponsor
Charite University, Berlin, Germany
Condition
Schizophrenia
CompletedNCT06236451

Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia

This study exists to learn from real-world information that can show how a medication treatment fits into care. Researchers are trying to understand whether a medication treatment can better support energy, concentration, and everyday functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
India
Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Condition
Schizophrenia
CompletedNCT04147897

Implementing mHealth for Schizophrenia in Community Mental Health Settings

This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand what helps a digital app or remote support tool stay useful, realistic, and easier to follow over time.

SchizophreniaOtherFrom 18 Years to 100 Years
Countries
United States
Sponsor
University of Washington
Condition
Schizophrenia
CompletedNCT06061952

CAE for Poorly Adherent Individuals With Schizophrenia

This study exists to see whether questionnaires and follow-up reports is workable and worth testing more broadly. Researchers are trying to understand whether questionnaires and follow-up reports can make support easier to access outside standard clinic visits.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
University Hospitals Cleveland Medical Center
Condition
Schizophrenia
CompletedNCT04779177

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

This study exists to better understand the safety of this type of care and how manageable it feels in practice. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

SchizophreniaOtherFrom 13 Years to 17 Years
Countries
United States
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
CompletedNCT04846868

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

This study exists to learn from real-world information that can show how the medication Iclepertin fits into care. Researchers are trying to understand whether the medication Iclepertin can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Australia, Brazil, Canada, China, Colombia, Germany, Greece, Italy, Japan, Mexico, New Zealand, Norway, Philippines, Poland, Sweden, Turkey, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT04317807

R33: Levetiracetam in Early Psychosis

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 16 Years to 40 Years
Countries
United States
Sponsor
NYU Langone Health
Condition
Schizophrenia
CompletedNCT06179108

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

This study exists to compare options and see whether the medication LB-102 offers something meaningfully different. Researchers are trying to understand how people respond to the medication LB-102 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
LB Pharmaceuticals Inc.
Condition
Schizophrenia
TerminatedNCT05368558

Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Japan, Taiwan
Sponsor
AbbVie
Condition
Schizophrenia
CompletedNCT06067984

An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
Click Therapeutics, Inc.
Condition
Schizophrenia
CompletedNCT04457310

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

This study exists to understand what helps blood tests and biological markers work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 45 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
Schizophrenia | Clinical Trials | HopeStage Research